who should take semaglutide for weight loss FDA Approves Oral Semaglutide: First GLP-1 Pill Semaglutide GLP-1 Medical Weight Loss

The FDA Wegovy prescribing information describes semaglutide as used with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in eligible adults

Patients often report: Low mood Increased stress sensitivity Emotional fatigue Reduced drive Iron infusions may help stabilize mood when iron deficiency is contributing to neurotransmitter imbalance

But not all CJC-1295 formulations are the same

The drugs US patent expires in the 2030s.

Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S

While early clinical trials showed manageable side effects, post-marketing surveillance has revealed more severe complications that require closer scrutiny